Teva Pharmaceutical (TEVA -0.2%) says data from its Phase III Glatiramer Acetate Low-Frequency...

|About: Teva Pharmaceutical Industr... (TEVA)|By:, SA News Editor

Teva Pharmaceutical (TEVA -0.2%) says data from its Phase III Glatiramer Acetate Low-Frequency Administration study shows a significant reduction in annual relapse rates and number of lesions in patients with relapsing-remitting multiple sclerosis, or RRMS. Detailed study results will be presented at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Lyon, France on October 13.